Status:
COMPLETED
Follow-up in Rivaroxaban Patients in Setting of Thromboembolism
Lead Sponsor:
King's College Hospital NHS Trust
Collaborating Sponsors:
Bayer
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18-99 years
Brief Summary
In patients with acute clots (deep vein thrombosis or pulmonary embolism) the investigators will collect real world data on their short and long term outcomes. The investigators hypothesise that in pa...
Detailed Description
United Kingdom-only prospective, non-interventional, investigator-led, multi-centre, single cohort, registry. The observation period for each patient covers the treatment period with rivaroxaban and f...
Eligibility Criteria
Inclusion
- Patients aged 18 years or older with an objectively verified diagnosis of DVT and/or PE and treated according to routine clinical practice with Rivaroxaban
Exclusion
- Patients in whom follow-up is unlikely or impossible
- Patients unable to give consent
- Patients who receive heparin therapy for more than 48 hours
- Patients who receive more than one dose of warfarin
- Patients with an indication for anticoagulation other than DVT and/or PE
- All contraindications listed in the local product information (SmPC) will form part of the exclusion criteria
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
1343 Patients enrolled
Trial Details
Trial ID
NCT02248610
Start Date
November 1 2014
End Date
July 31 2020
Last Update
August 12 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Basingstoke Hospital
Basingstoke, United Kingdom
2
Bournemouth Hospital
Bournemouth, United Kingdom
3
Kings College Hospital NHS Foundation Trust
London, United Kingdom, SE5 9RS
4
Salisbury Hospital
Salisbury, United Kingdom